TY - JOUR
T1 - Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencing
AU - CONRAD, THOMAS
AU - NTINI, EVGENIA
AU - LANG, BENJAMIN
AU - COZZUTO, LUCA
AU - ANDERSEN, JESPER B.
AU - MARQUARDT, JENS U.
AU - PONOMARENKO, JULIA
AU - TARTAGLIA, GIAN GAETANO
AU - ØROM, ULF A.VANG
N1 - Funding Information:
This work was funded by the Sofja Kovalevskaja Award of the Alexander von Humboldt Foundation and the Hallas Møller Award of the Novo Nordisk Foundation (U.A.V.Ø.).
Publisher Copyright:
© 2020 Conrad et al.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - MicroRNA expression is important for gene regulation and deregulated microRNA expression is often observed in diseases such as cancer. The processing of primary microRNA transcripts is an important regulatory step in microRNA biogenesis. Due to low expression level and association with chromatin, primary microRNAs are challenging to study in clinical samples where input material is limited. Here, we present a high-sensitivity targeted method to determine processing efficiency of several hundred primary microRNAs from total RNA that requires relatively few RNA sequencing reads. We validate the method using RNA from HeLa cells and show the applicability to clinical samples by analyzing RNA from normal liver and hepatocellular carcinoma. We identify 24 primary microRNAs with significant changes in processing efficiency from normal liver to hepatocellular carcinoma, among those the highly expressed miRNA-122 and miRNA-21, demonstrating that differential processing of primary microRNAs is occurring and could be involved in disease.With our method presented here we provide means to study pri-miRNA processing in disease from clinical samples.
AB - MicroRNA expression is important for gene regulation and deregulated microRNA expression is often observed in diseases such as cancer. The processing of primary microRNA transcripts is an important regulatory step in microRNA biogenesis. Due to low expression level and association with chromatin, primary microRNAs are challenging to study in clinical samples where input material is limited. Here, we present a high-sensitivity targeted method to determine processing efficiency of several hundred primary microRNAs from total RNA that requires relatively few RNA sequencing reads. We validate the method using RNA from HeLa cells and show the applicability to clinical samples by analyzing RNA from normal liver and hepatocellular carcinoma. We identify 24 primary microRNAs with significant changes in processing efficiency from normal liver to hepatocellular carcinoma, among those the highly expressed miRNA-122 and miRNA-21, demonstrating that differential processing of primary microRNAs is occurring and could be involved in disease.With our method presented here we provide means to study pri-miRNA processing in disease from clinical samples.
UR - http://www.scopus.com/inward/record.url?scp=85093522395&partnerID=8YFLogxK
U2 - 10.1261/rna.076240.120
DO - 10.1261/rna.076240.120
M3 - Journal articles
C2 - 32669295
AN - SCOPUS:85093522395
SN - 1355-8382
VL - 26
SP - 1726
EP - 1730
JO - RNA
JF - RNA
IS - 11
ER -